Takeda Pharmaceutical Co. reported positive Phase 2b trial results on June 3, 2024, for TAK-861, an oral treatment for narcolepsy type 1, demonstrating significant improvements over 8 weeks; they plan to initiate Phase 3 trials soon. The trial showed statistically significant enhancements in sleep latency and reduced cataplexy frequency, indicating TAK-861's potential as a first-in-class treatment.